Business

Coherus BioSciences, Inc. (CHRS) Under Analyst Spotlight

Coherus BioSciences, Inc. (CHRS) Under Analyst Spotlight

Other research analysts have also issued research reports about the company. BMO Capital Markets reiterated an "outperform" rating and set a $54.00 price objective on shares of Coherus Biosciences in a research report on Monday. 01/20/2016 - Credit Suisse began new coverage on Coherus BioSciences , Inc. giving the company a "outperform" rating. In other news, insider Alan C.


G-7 countries call for renewed common effort against cybercrime

G-7 countries call for renewed common effort against cybercrime

The American banker and former hedge fund manager made the comments in the Italian port city of Bari , where finance ministers and central bank governors from the Group of Seven nations ended their two-day meeting on Saturday. The lack of consensus was reflected in the blandness of the meeting's closing statement , which avoided a precise trade agreement. They include faster-than-expected US interest rate increases, which could affect some developing economies by triggering an outflow of ...



RI Delegation Applauds Selection Of Independent Counsel For Russia Probe

Mr Comey was heading the bureau's Russian Federation and Trump campaign investigation. "I think that's an open question", said Democratic Senator Chris Coons of DE when asked whether Comey would appear before Congress, adding that it remained to be seen "how ongoing congressional investigations will be coordinated with the special counsel".



Trump administration gives notice on NAFTA renegotiations

Brian Hengesbaugh, data protection partner at Baker McKenzie in Chicago, told Bloomberg BNA May 18 that data privacy and localization provisions requiring companies to store personal data within a country's borders should be included in all trade deals.


Snap shares plummet after net loss

Snap shares plummet after net loss

The company attributes $2 billion of that to "stock-based compensation". The operating expenses for the quarter were $196 million. Brian Wieser, an analyst at Pivotal Research commented that the company's revenue was "a relatively disappointing number".